CASP3 and prostate adenocarcinoma: Finally, high CASP3 expression was associated with low PFI in ACC (p < 0.001), KIRC (p = 0.018), LGG (p < 0.001), LUAD (p = 0.044), prostate adenocarcinoma (PRAD; p = 0.002), and UVM (p = 0.002, Figure 4G).